在大型管理护理人群中,每名有效治疗的风湿性关节炎患者的生物成本:一项回顾性队列研究
Tao Gu1, Neel Shah2, Gaurav Deshpande1
1HealthCore, Wilmington, DE.
Journal of health economics and outcomes research
|September 4, 2023
概括
这项研究发现,乙太是最具成本效益的第一线生物治疗类风湿性关节炎 (RA) 的药物. 它在美国管理护理人口中,每名有效治疗的患者的1年生物成本最低.
科学领域:
- 药物经济学 药物经济学
- 相对有效性研究研究比较
- 类风湿病学 类风湿病学
背景情况:
- 以前,行政索赔数据库缺乏临床结果,限制了它们在类风湿性关节炎 (RA) 比较有效性研究中的使用.
- 一个经过验证的基于索赔的算法现在可以在同一数据库中估计生物有效性和成本.
研究的目的:
- 实施一个经过验证的基于声明的算法,以计算在中度至重度的RA中,一线生物药物对每名有效治疗的患者的1年生物成本.
- 为了比较阿塔塔塞普特,阿达利穆马布,克尔科利祖马布,佩戈尔,伊坦塞普特,戈利穆马布和因弗利西马布的成本效益.
主要方法:
- 从2009年7月到2013年1月,使用HealthCore综合研究数据库 (HIRDSM) 进行了回顾性队列研究.
- 定义的指数事件作为RA患者的第一个生物学主张,年龄在18-63岁之间,先前有RA诊断.
- 有效性算法评估了坚持,剂量稳定性,缺乏新疗法,以及12个月后的有限葡萄糖皮质激素使用.
主要成果:
- 该研究包括4844名患者,平均第一年生物成本从14,795美元 (golimumab) 到19,520美元 (abatacept).
- 埃坦尼塞普特显示,每位有效治疗的患者的平均第一年生物成本最低 (50,217美元).
- 与戈利马布,阿达利马布,阿塔塔塞普特,克尔科利祖马布佩戈尔和因弗力西马布相比,对于乙坦塞普特,每名有效治疗的患者,观察到显著较低的成本 (p<0.001).
结论:
- 在对RA进行评估的第一线生物药物中,Etanercept对每名有效治疗的患者的1年生物成本最低.
- 经过验证的基于索赔的算法提供了一种可行的方法,用于评估大型管理护理人群中的生物成本效益.
相关概念视频
01:11Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147
01:21Rheumatic Heart Disease III: Medical Management
12
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
12
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
01:20Rheumatic Heart Disease IV: Nursing Management
18
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
18